Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 2/20 | 0.42 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.42 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 8/20 | 0.40 |
| ▸ | CA2 | P00918 | 6/20 | 0.40 |
| ▸ | CA4 | P22748 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | DRD1 | P21728 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4938839 | 1.00 | MAOB (0.42) | MAOBSLC1A1FOLH1CA1CA2 | |
| SCHEMBL1144138 | 1.00 | MAOB (0.42) | MAOBSLC1A1FOLH1CA1CA2 | |
| SCHEMBL8059292 | 0.99 | MAOB (0.43) | MAOBSLC1A1FOLH1CA1CA2 | |
| SCHEMBL8068462 | 0.99 | MAOB (0.43) | MAOBSLC1A1FOLH1CA1CA2 | |
| SCHEMBL8068485 | 0.99 | MAOB (0.43) | MAOBSLC1A1FOLH1CA1CA2 | |
| SCHEMBL8059372 | 0.95 | SLC1A1 (0.44) | MAOBSLC1A1FOLH1CA1CA2 | |
| SCHEMBL6443574 | 0.94 | FOLH1 (0.46) | MAOBSLC1A1FOLH1CA1CA2 | |
| SCHEMBL7594884 | 0.93 | SLC1A1 (0.47) | MAOBSLC1A1FOLH1CA1CA2 | |
| SCHEMBL29742385 | 0.93 | MAOB (0.42) | MAOBSLC1A1FOLH1CA1CA2 | |
| SCHEMBL6443585 | 0.91 | MAOB (0.38) | MAOBSLC1A1FOLH1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 146 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4077271-B1 | CALCIUM BOPTA COMPLEX | BRACCO IMAGING SPA (IT) | 2025-10-15 | — | — | EP | claimed |
| US-20250064988-A1 | MRI-AGENT LOADED PLATELET COMPOSITIONS AND METHODS OF PREPARING AND USING THE SAME | CELLPHIRE, INC. (US) | 2025-02-27 | — | — | US | claimed |
| CN-118718024-A | Magnetic resonance contrast agent for targeted detection of collagen molecular structural denaturation and preparation method and application thereof | 中山大学附属第五医院 | 2024-10-01 | — | — | CN | claimed |
| WO-2024194511-A1 | COMPOSITION FOR PURIFYING WATER | UNIVERSIDAD DE ALMERÍA (ES) | 2024-09-26 | — | — | WO | claimed |
| WO-2023245169-A1 | ANTIMICROBIAL PEPTIDE COMBINATIONS | Vestaron Corporation (US) | 2023-12-21 | — | — | WO | claimed |
| WO-2023220694-A1 | MRI-AGENT LOADED PLATELET COMPOSITIONS AND METHODS OF PREPARING AND USING THE SAME | CELLPHIRE, INC. (US) | 2023-11-16 | — | — | WO | claimed |
| US-11667601-B2 | Calcium BOPTA complex | BRACCO IMAGING S.P.A. (IT) | 2023-06-06 | — | — | US | claimed |
| CN-115737835-A | Use of substance specifically binding to ICAM1 in preparation of therapeutic or diagnostic product for thyroid cancer | 浙江省肿瘤医院 | 2023-03-07 | — | — | CN | claimed |
| US-20230046541-A1 | CALCIUM BOPTA COMPLEX | BRACCO IMAGING S.P.A. (IT) | 2023-02-16 | — | — | US | claimed |
| US-20220370646-A1 | PHARMACEUTICAL COMPOSITIONS OF GD-BASED CONTRAST AGENTS | BRACCO IMAGING S.P.A. (IT) | 2022-11-24 | — | — | US | claimed |
| EP-4048322-A1 | PHARMACEUTICAL COMPOSITIONS OF GD-BASED CONTRAST AGENTS | Bracco Imaging SPA (IT) | 2022-08-31 | — | — | EP | claimed |
| CN-114845990-A | Calcium BOPTA complex | 伯拉考成像股份公司 | 2022-08-02 | — | — | CN | claimed |
| US-11383008-B2 | Surface-modified polymeric substrates grafted with a properties-imparting compound using clip chemistry | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2022-07-12 | — | — | US | claimed |
| CN-114099717-A | Tumor fibroblast activation protein targeted magnetic resonance contrast agent and preparation and application thereof | 同济大学 | 2022-03-01 | — | — | CN | claimed |
| EP-4739689-A1 | NOVEL BISPIDINE-BASED METAL CHELATING LIGANDS DISPLAYING GOOD RELAXIVITY | Université de Strasbourg (FR) | 2026-05-13 | — | — | EP | disclosed |
| EP-4727957-A2 | PVD1 VARIANT POLYPEPTIDES FOR PEST CONTROL | Vestaron Corporation (US) | 2026-04-22 | — | — | EP | disclosed |
| US-12576167-B2 | Gadolinium-based compound, method for producing same, and MRI contrast agent containing same | KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2026-03-17 | — | — | US | disclosed |
| CN-108712915-B | Method for improving dispersion stability of nanoparticles serving as T1 type magnetic resonance imaging contrast agent | 延世大学校产学协力团 | 2022-03-08 | — | — | CN | disclosed |
| US-20220062444-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING GD-COMPLEXES AND POLYARYLENE ADDITIVES | BRACCO IMAGING S.P.A. (IT) | 2022-03-03 | — | — | US | disclosed |
| CN-114099717-A | Tumor fibroblast activation protein targeted magnetic resonance contrast agent and preparation and application thereof | 同济大学 | 2022-03-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11667601-B2 | Calcium BOPTA complex | TMCO1, SLC8A1, CA5A | MAOB 3888/4885SLC1A1 225/4885FOLH1 413/4885 |
| US-20220370646-A1 | PHARMACEUTICAL COMPOSITIONS OF GD-BASED CONTRAST AGENTS | GMNN, GRN, GBA1 | MAOB 1700/4885SLC1A1 1505/4885FOLH1 1261/4885 |
| US-12576167-B2 | Gadolinium-based compound, method for producing same, and MRI contrast agent containing same | LGALS1, CLIC1, LGALS2 | MAOB 2664/4885SLC1A1 298/4885FOLH1 350/4885 |
| US-20220062444-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING GD-COMPLEXES AND POLYARYLENE ADDITIVES | GRN, GALC, ABCB11 | MAOB 1564/4885SLC1A1 1409/4885FOLH1 1318/4885 |
| US-11383008-B2 | Surface-modified polymeric substrates grafted with a properties-imparting compound using clip chemistry | CLASP1, MACF1, MICA | MAOB 853/4885SLC1A1 3554/4885FOLH1 1269/4885 |
| US-20230046541-A1 | CALCIUM BOPTA COMPLEX | TMCO1, SLC8A1, CA5A | MAOB 3888/4885SLC1A1 225/4885FOLH1 413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.